Pharmacy OneSource Blog

Complete the USP 797 and 800 Compliance Study and Gap Analysis and receive a free Action Plan customized to your facility

Posted on 05/18/17

Observation_of_Compounding_technique_2.jpg The 2017 USP <797> & <800> Compliance Study, led by sterile compounding experts and Study Co-Directors Eric Kastango, RPh, MBA, FASHP and Kate Douglass, MS, RN, CRNI is now open through June 30th 2017.

This study provides you with the opportunity to perform a complete USP <797> and <800> gap analysis or your have the option to answer questions related to just <797> or <800> all from one login. Gap analyses are key to improving and monitoring compliance efforts.

The information and insights gained from this year's Study will be very valuable to the compounding industry. These results will assist in benchmarking our progress and will help identify where additional resources and focus is required in order to improve sterile compounding practice and patient safety. We are committed to this Study and eagerly encourage your participation.

The 2017 USP Compliance Study uses a sophisticated, web-based Gap Analysis Tool that Kate and Eric have developed and have used to conduct studies over the last several years. This tool is available at NO CHARGE to all study participants and in return for your participation, you will receive a highly detailed automatically generated Action Plan that is based on your answers to the survey. The Action Plan provides documentation that can be used to begin or continue sterile compounding practice improvements at your location.

The survey takes 60 to 90 minutes to complete but does not need to be completed in one sitting. This year, a PDF document of all survey questions will also be provided to facilitate offline data collection for those who might find this useful. This document will be available for download after you have registered and completed the first two informational sections of the survey.

It should be noted that ALL INDIVIDUAL FACILITY RESULTS ARE CONFIDENTIAL - ONLY AGGREGATE DATA WILL BE USED IN THE STUDY REPORT. 

Thank you in advance for your participation in The 2017 USP <797> and <800> Compliance Study. The results will help industry experts learn more about the successes and challenges relative to USP <797> and <800> compliance. With valuable insight, it becomes easier to target additional strategies to promote best-practice sterile compounding. The results of the Study will be published this fall in Pharmacy Purchasing & Products magazine. If you have any questions, please contact the Study Team at  studyteam@797study.com.
 New Call-to-action

Topics: Sterile Compounding

About the Author

CriticalPoint Study